Growth Metrics

Fennec Pharmaceuticals (FENC) Income towards Parent Company (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Income towards Parent Company readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 242.11% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 million, a 1651.93% decrease, with the full-year FY2025 number at -$9.7 million, down 180.8% from a year prior.
  • Income towards Parent Company hit $2.1 million in Q4 2025 for Fennec Pharmaceuticals, up from -$623000.0 in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $12.9 million in Q1 2024 to a low of -$8.0 million in Q3 2022.
  • Median Income towards Parent Company over the past 5 years was -$3.9 million (2021), compared with a mean of -$2.9 million.
  • The widest YoY moves for Income towards Parent Company: up 316.58% in 2024, down 222.47% in 2024.
  • Fennec Pharmaceuticals' Income towards Parent Company stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then soared by 62.03% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then surged by 242.11% to $2.1 million in 2025.
  • The last three reported values for Income towards Parent Company were $2.1 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.